PERKINELMER INC Stock Price, News & Analysis

PerkinElmer (NYSE: PKI) anticipates a remarkable 98% growth in reported revenue and 90% in organic revenue for Q1 ending April 4, 2021. This performance is attributed to strong core demand, with 10% organic growth in non-COVID-19 segments and approximately $535 million from COVID-19 solutions. Financial results will be disclosed on May 4, 2021, alongside a conference call led by CEO Prahlad Singh and CFO Jamey Mock. Additionally, Steve Willoughby will assume the role of VP of Investor Relations starting May 5, 2021.

PerkinElmer's Horizon Discovery has expanded its gene editing portfolio with new CRISPR modulation (CRISPRmod) reagents, enabling gene repression at the transcriptional level. This includes synthetic single guide RNAs for CRISPR interference and a novel dCas9-SALL1-SDS3 repressor, enhancing gene modulation performance. These advancements aim to aid researchers in understanding disease pathways and exploring therapeutic options. PerkinElmer reported approximately $3.8 billion in revenue in 2020 and serves customers globally.

PerkinElmer (NYSE: PKI) has introduced two new Research Use Only (RUO) solutions: PKamp™ VariantDetect™ SARS-CoV-2 RT-PCR Assay and Next Generation Sequencing-based NEXTFLEX® Variant-Seq™ SARS-CoV-2 Kit. These assays allow laboratories to analyze genomic mutations in SARS-CoV-2 variants from previously positive samples. The PKamp assay detects mutations related to dominant variants like B.1.1.7 and B.1.351, enhancing COVID-19 testing capabilities. PerkinElmer continues to innovate amidst evolving public health challenges.

PerkinElmer, Inc. (NYSE: PKI) has finalized its acquisition of Oxford Immunotec Global PLC, recognized for its T-SPOT^®.TB tuberculosis test. The acquisition aims to enhance PerkinElmer's diagnostic capabilities, leveraging automation and commercial access to expand market reach for tuberculosis testing. Oxford Immunotec reported revenues of $73.74 million in 2019. This strategic move aligns with PerkinElmer's mission to innovate for better health outcomes worldwide.

PerkinElmer (NYSE: PKI) has priced a $400 million offering of 2.550% Senior Notes due 2031 and 3.625% Senior Notes due 2051. The offering, expected to close on March 8, 2021, aims to utilize approximately $561 million of net proceeds to repay debt related to its acquisition of Oxford Immunotec Global PLC and to refinance existing senior notes. This strategic move aligns with the company's focus on innovation and maintaining a healthy financial position.

PerkinElmer, Inc. (NYSE: PKI) will present at the Barclays Global Healthcare Conference on March 10, 2021, from 9:45 a.m. to 10:10 a.m. ET. The presentation will feature Prahlad Singh, president and CEO, discussing the Company's strategic priorities. Investors can access a live audio webcast of the event on PerkinElmer's website, with a replay available for 90 days post-event. In 2020, PerkinElmer reported revenues of approximately $3.8 billion, employs over 14,000 people, and serves clients in 190 countries, being part of the S&P 500 Index.

PerkinElmer (NYSE: PKI) has launched its COVID-19 Antigen Test for the qualitative detection of SARS-CoV-2 antigen, yielding results in 15 minutes. This test, suitable for professional use in various settings, is already available in over 30 countries. Clinical studies show a sensitivity rate exceeding 97% and 100% specificity, indicating no false positives. The company emphasizes the need for reliable antigen testing to support reopening strategies globally. The test complements PerkinElmer's existing portfolio, which includes high throughput RNA extraction and RT-PCR solutions.

PerkinElmer (NYSE: PKI) provided an update on the accreditation of its COVID-19 Valencia Branch Laboratory (VBL) in collaboration with the California Department of Public Health. The VBL commenced operations on November 1, 2020, and has capacity for 100,000 tests daily. Following a recent inspection, PerkinElmer addressed identified deficiencies and expects a positive response from the College of American Pathologists (CAP) accreditation. The laboratory has tested over 1.5 million samples. PerkinElmer emphasizes its commitment to quality and transparency throughout the accreditation process.

PerkinElmer, a leading global innovator, will present at the 41st Annual Cowen Health Care Conference on March 1, 2021, from 12:20 to 12:50 p.m. ET. CEO Prahlad Singh will discuss the company's strategic priorities. A live audio webcast will be available on the company's Investors page, with a replay accessible for 90 days after the event. In 2020, PerkinElmer reported approximately $3.8 billion in revenue and employs over 14,000 people across 190 countries, contributing to the S&P 500 Index.